New treatments in early age-related macular degeneration

5 September 2012
Volume 13, Issue 3
AMD

This article reviews the various treatment options available as prophylactic therapy for early AMD.

Introduction

Age-related macular degeneration (AMD) is the leading cause of blindness amongst the elderly in the western world. An estimated 30% of people aged 75 years or older show at least the early manifestations of AMD, which consists of yellow deposits (drusen) and/or pigment clumps. In the UK, there are 25 000 new cases of wet AMD each year and the current intravitreal anti-VEGF therapy costs 1% of the annual £9 billion NHS budget. Currently, there is no treatment to prevent progression of the earlier stages of AMD. Prevention is better than cure and there is ongoing research into finding a preventive therapy for this disease. This article reviews the various treatment options available as prophylactic therapy for early AMD.

Sign in to continue

Forgotten password?
Register

Sign in to view the article

Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

A glance at what’s happening in the world of technology.

Eye health issues that are making the news.

A glance at what’s happening in the world of technology.